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ABSTRACT
Background and Objectives: Although recent lipid-lowering therapies are effective in reducing low density lipoprotein-
cholesterol (LDL-C) levels, many patients treated with lipid-lowering agents do not achieve target LDL-C levels, especially in 
very high risk patients. The aim of this study is to compare the effect of ezetimibe/simvastatin 10/20 mg and atorvastatin 20 mg 
on achieving a target LDL-C goal in very high risk patients. Subjects and Methods: A total of 74 patients with very high risk 
were enrolled in the study. Very high risk patients were defined as patients that displayed established cardiovascular disease 
with multiple major risk factors, poorly controlled risk factors, multiple risk factors of the metabolic syndrome and acute co-
ronary syndromes. Patients were randomized into two groups: ezetimibe/simvastatin 10/20 mg (n=36) and atorvastatin 20 mg 
(n=38). Follow-up lipid profile was obtained 6 weeks later. A target goal of LDL-C was defined as less than 70 mg/dL at follow-
up. Results: Baseline clinical and laboratory data were similar between the two groups. Achieving a target LDL-C goal was 
observed in 41.7% of Group 1 and 44.7% of Group 2 at 6 weeks (p=0.82). Changes in other lipid profiles were not significantly 
different but the tolerability of the two groups was similar. Conclusion: Ezetimibe/simvastatin 10/20 mg and atorvastatin 20 
mg showed similar effects in achieving target LDL-C levels in patients with very high risk. (Korean Circ J 2011;41:149-153)
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Introduction
The importance of lowering low density lipoprotein-choles-
terol (LDL-C) levels to prevent major cardiovascular prob-
lems has been well known and current guidelines emphasize 
the need to reduce LDL-C to target levels.
1)2) Moreover, in high-
risk or moderately high-risk persons, it is advised that the in-
tensity of therapy be sufficient to achieve at least 30 to 40% re-
duction in LDL-C levels.
3) Thus, more effective lipid-lowering 
therapies are needed to reach the established LDL-C goal. To 
attain optimal LDL-C levels, higher doses of more potent st-
atins (3-hydroxy-3-methylglutaryl coenzyme A reductase in-
hibitors) provide greater reduction in LDL-C. Recently, the 
challenge of attaining more aggressive LDL-C goals has sti-
mulated research into possible new combinations of lipid-lo-
wering agents with complementary mechanisms of actions. 
The major effect of statin is to reduce LDL-C by inhibiting 
cholesterol synthesis. Ezetimibe is a novel cholesterol absorp-
tion inhibitor that prevents the absorption of cholesterol by 
inhibiting the passage of cholesterol of dietary and biliary ori-
gin across the intestinal wall.
4)5) Clinical trials have shown that 
the co-administration of ezetimibe with simvastatin, a combi-
nation therapy that inhibits cholesterol biosynthesis and blocks 
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than any one of the agents alone.
6)7) Heart Protection Study 
(HPS)
8) and the Pravastatin or Atorvastatin Evaluation and   
Infection Therapy trial
9) suggested that cardiovascular event 
reduction may be obtained by reducing LDL-C levels to sub-
stantially below 100 mg/day. On the basis of data from 2 stud-
ies, National Cholesterol Education Program Adult Treatment 
Panel (NCEP ATP) III recommended that an LDL-C goal of <70 
mg/dL is a reasonable clinical strategy when risk is very high.
3)
The primary objective of the current trial was to compare the 
effect of ezetimibe/simvastatin 10/20 mg and atorvastatin 20 
mg in achieving the target LDL-C goal of <70 mg/dL in sub-
jects with very high risk. The secondary objective was to com-
pare the effect of ezetimibe/simvastatin 10/20 mg with that 
of atorvastatin 20 mg on the lipid profile except LDL-C.
Subjects and Methods
Study design
This single center, randomized, open-label study was design-
ed to evaluate the efficacy and tolerability of ezetimibe/sim-
vastatin 10/20 mg and atorvastatin 20 mg in very high risk pa-
tients. The protocol was approved by appropriate institutional 
review boards, and all patients provided written informed con-
sent before initiation of any study procedure. Patients discon-
tinued fibrate therapy for a 12 weeks wash-out period and all 
other lipid-lowering therapy 4 weeks before the start of the 
study. Patients were randomized after coronary angiography 
to ezetimibe/simvastatin 10/20 mg or atorvastatin 20 mg once 
daily before bedtime in a 1:1 ratio using a computer-gener-
ated random table. Patients were asked to count their unused 
medication at the last day of treatment and compliance was 
assessed by counting the remaining tablets.
Based on the previous study,
10) with a sample size of appro-
ximately 36 patients per treatment arm, this study had 80% 
effectiveness to detect a 6.9% difference, assuming a standard 
deviation (SD) of 20.1% and a significance level of 0.05 (1-sided). 
Study population
From February 2008 to October 2008, patients with coro-
nary artery disease and documented hypercholesterolemia 
(LDL-C >100 mg/dL and ≤250 mg/dL) at screening were en-
rolled. Patients were 20 to 79 years of age. Very high risk pa-
tients were defined as those with the presence of established 
cardiovascular disease plus 1) multiple major risk factors (es-
pecially diabetes), 2) poorly controlled risk factors {especial-
ly continued cigarette smoking, uncontrolled blood pressure 
and low high density lipoprotein-cholesterol (HDL-C)}, 3) 
multiple risk factors of the metabolic syndrome {especially 
high triglycerides (TG) ≥200 mg/dL plus non HDL-C ≥130 
mg/dL with low HDL-C (<40 mg/dL), impaired fasting glu-
cose and central obesity} and 4) patients with acute coronary 
syndromes (ACS).
3) Other criteria included fasting serum 
TG <400 mg/dL and aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), or creatine kinase (CK) level ≤1.5 
times the upper limit of normal levels.
Exclusion criteria included conditions or medications that 
could have affected lipid levels, such as patients with conges-
tive heart failure defined by the New York Heart Association 
class III or IV, as well as patients with poorly controlled hyper-
tension (systolic blood pressure >180 mmHg or diastolic blo-
od pressure >100 mmHg), evidence of uncontrolled endocr-
ine or metabolic disease known to influence serum lipid pro-
file, and concomitant excluded drug use (i.e. immunosup-
pressants, corticosteroids, or potent inhibitors of cytochrome 
P450 3A4).
Efficacy and tolerability
Measurements of lipid parameters were performed random-
ly 6 weeks after treatment. Blood samples were taken after fast-
ing for 12 hours. In patients with ACS, baseline blood samples 
were collected between 24 and 48 hours of diagnosis. The pri-
mary efficacy end point was the percentage of patients achiev-
ing the LDL-C goal (<70 mg/dL) of NCEP ATP III guideline 
after 6 weeks of treatment. Secondary efficacy end points in-
cluded the percentage changes of the lipid profile such as to-
tal cholesterol (TC), TG, HDL-C, non HDL-C, apolipoprotein 
(Apo) B and high-sensitivity C-reactive protein (hs-CRP) as 
well as the ratio of LDL-C and HDL-C (LDL-C/HDL-C) at 
follow-up.
Tolerability assessment included the collection of adverse 
events, physical examination and vital signs. Laboratory mea-
surements included AST, ALT, CK, blood urea nitrogen and 
creatinine. Pre-specified adverse events included those that 
were gastrointestinal-related and hepatitis-related adverse 
events as well as incidences of clinically significant elevations 
in AST and ALT, which were ≥3 times the upper limit of nor-
mal levels, and CK elevations, which were ≥5 times the upper 
limit of normal levels, with or without muscle symptoms.
Statistical analysis
Efficacy analyses of biological parameters were performed 
in patients who had taken at least one dose of randomized me-
dications, had a baseline efficacy measurement and at least 
one efficacy measurement during the treatment period. The 
changes of each parameter were calculated from the mean± 
SD and differences were statistically assessed by an unpaired 
t-test. Proportions were compared by a chi-square test with 
95% confidence intervals. All statistical tests were two-sided, 
with the level of significance being set at p<0.05.
Results
Patients
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udy and randomized in similar numbers with ezetimibe/sim-
vastatin 10/20 mg (n=42) or atorvastatin 20 mg (n=43). Of 
these, 36 patients (85.7%) in the ezetimibe/simvastatin group 
and 38 patients (88.4%) in the atorvastatin group successfully 
completed the 6 week treatment period. Eleven (12.9%) pa-
tients were discontinued from the study. Seven patients were 
lost at follow-up and four patients showed protocol violation.
There were no clinically significant differences in baseline 
demographic or disease characteristics across the two treat-
ment groups (Table 1). All patients received a loading dose of 
aspirin (300 mg) and clopidogrel (300 mg) before coronary an-
giography. During follow-up, the anti-platelet regimen was 
not different (83.3% in the ezetimibe/simvastatin group vs. 
86.8% in the atorvastatin group in case of dual anti-platelet th-
erapy, 11.1% in the ezetimibe/simvastatin group vs. 2.6% in 
the atorvastatin group, in case of triple anti-platelet therapy, 
p=0.194. Furthermore, beta blocker (83.3% in the ezetimibe/
simvastatin group vs. 78.9% in the atorvastatin group, p=0.769) 
and angiotensin-converting enzyme inhibitor (77.8% in the 
ezetimibe/simvastatin group vs. 73.7% in the atorvastatin 
group, p=0.789) were similar between two groups. The ma-
jority of study participants presented ACS (66.7% in the 
ezetimibe/simvastatin group vs. 65.8% in the atorvastatin 
group, p=1.000). Among ACS patients, 1 patient in the ezet-
imibe/simvastatin group and 2 patients in the atorvastatin 
group took statin before enrollment. However, the washout 
period was at least a year. Baseline lipid variables were simi-
lar between the two groups. 
Efficacy
The incidence of achieving target LDL-C levels (<70 mg/
dL) was not different between the two groups (41.7% in the 
ezetimibe/simvastatin group vs. 44.7% in the atorvastatin gr-
oup, p=0.818). At follow-up, percent reduction of LDL-C level 
was 41.1% in the ezetimibe/simvastatin group and 44.2% in 
the atorvastatin group (p=0.715) (Table 2). For the secondary 
efficacy end points, both the ezetimibe/simvastatin and atorv-
astatin groups produced significant decrease from the base-
line in TC (28.3% vs. 29.9%, p=0.639), TG (-6.7% vs. -1.3, p= 
0.717), HDL-C (-4.4% vs. -2.3%, p=0.699, non HDL-C (31.4% 
vs. 37.6%, p=0.404), Apo B (28.7% vs. 34.8%, p=0.318) and hs-
CRP (-15.1% vs. -17.9%, p=0.961). Our results showed that the 
LDL-C/HDL-C ratio at follow-up was not different between 
the two groups (0.18 vs. 0.19, p=0.910).
Tolerability
Treatment with ezetimibe/simvastatin 10/20 mg and ator-
vastatin 20 mg was generally well tolerated and the mean com-
pliance was over 99% in both groups. Overall, the prevalence 
Table 1. Baseline characteristics of the patient groups
Ezetimibe/
Simvastatin Atorvastatin p
Age (years) 60.5±9.5 62.6±9.7 0.348 
Male (%) 66.7 57.9 0.480 
Diabetes (%) 33.3 34.2 1.000 
Hypertension (%) 50.0  55.3 0.816 
Smoking (%) 27.8 42.1 0.230 
Metabolic syndrome with
  multiple risk factors (%) 25.0  36.8 0.321 
Clinical diagnosis (%)
AP/ACS 33.3/66.7 34.2/65.8 1.000 
Multi-vessel disease (%) 30.6 21.6 0.433 
Ejection fraction (%) 59.0±9.7 59.8±10.2 0.736 
Lipid profile
LDL-C (mg/dL) 134.1±23.2 132.1±30.6 0.759 
TC (mg/dL) 199.8±32.2 198.5±35.3 0.866 
TG (mg/dL) 138.7±78.1 130.3±51.9 0.585 
HDL-C (mg/dL) 45.2±9.8 46.1±9.8 0.704 
Non HDL-C (mg/dL) 151.9±36.6 150.0±37.2 0.827 
LDL-C/HDL-C ratio 03.11±0.90 02.98±0.90 0.557 
Apolipoprotein B (mEq/L) 100.7±30.9 095.0±26.3 0.393 
hs-CRP (mg/dL) 000.3±0.30 000.5±0.80 0.166 
AP: angina pectoris, ACS: acute coronary syndrome, LDL-C: low den-
sity lipoprotein-cholesterol, TC: total cholesterol, TG: triglyceride, 
HDL-C: high density lipoprotein-cholesterol, hs-CRP: high-sensiti-
vity C-reactive protein
Table 2. Lipid profile at follow-up and percentage change from ba-
seline for the patient groups
Ezetimibe/
Simvastatin
Atorvastatin p
At follow-up
    LDL-C (mg/dL) 077.2±21.0 072.9±20.5 0.370 
    TC (mg/dL) 141.1±26.7 136.8±26.3 0.497 
    TG (mg/dL) 122.2±63.4 121.3±68.6 0.951 
    HDL-C (mg/dL) 46.4±9.0 046.9±13.2 0.853 
    non HDL-C (mg/dL) 094.7±24.8 090.0±28.4 0.453 
    LDL-C/HDL-C ratio 00.18±0.45 00.19±0.28 0.910 
    Apolipoprotein B
      (mEq/L)
068.1±23.1 062.6±20.4 0.323 
    hs-CRP (mg/dL) 00.18±0.45 00.19±0.28 0.917 
Percentage change 
  from baseline (%)
    LDL-C 041.1±17.3 044.2±14.0 0.715 
    TC 028.3±14.6 029.9±13.4 0.639 
    TG 0-6.7±71.5 0-1.3±53.8 0.717 
    HDL-C 0-4.4±17.8 0-2.3±26.6 0.699 
    non HDL-C 031.4±38.7 037.6±21.8 0.404 
    Apolipoprotein B 028.7±24.9 034.8±22.1 0.318 
    hs-CRP  0-15.1±296.9 0-17.9±152.7 0.961 
LDL-C: low density lipoprotein-cholesterol, TC: total cholesterol, 
TG: triglyceride, HDL-C: high density lipoprotein-cholesterol, hs-CRP: 
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of adverse events were 2.8% in the ezetimibe/simvastatin 
group and 5.3% in the atorvastatin group (p=1.000). One pa-
tient in the ezetimibe/simvastatin group (2.8%) had gastro-
intestinal trouble such as dyspepsia and abdominal pain. In 
the atorvastatin group, one patient (2.6%) had diarrhea and 
one (2.6%) showed elevation of AST and ALT, which was ≥3 
times the upper limit of normal levels. No patient in either 
group had CK elevations of ≥5 times the upper limit of nor-
mal levels, with or without muscle symptoms.
Discussion
On the basis of HPS and PROVE-IT-Thrombolysis In Myo-
cardial Infarction (TIMI) 22, an LDL-C level of 100 mg/dL 
does not appear to be a threshold in high-risk patients and 
additional benefit may be obtained by reducing LDL-C lev-
els to substantially below 100 mg/dL.
11)12) NCEP ATP III re-
inforced an LDL-C level of 100 mg/dL to be a minimal goal of 
treatment of high-risk patients and an LDL-C goal of <70 
mg/dL to be an optional goal for very high-risk patients.
3) 
The present study examined the lipid-lowering efficacy and 
tolerability of ezetimibe/simvastatin 10/20 mg and atorvas-
tatin 20 mg in patients with very high-risk. The proportion of 
patients reaching an LDL-C level of less than 100 mg/dL was 
similar (86.1% in the ezetimibe/simvastatin group vs. 86.8% 
in the atorvastatin group). Achieving the target goal of <70 
mg/dL was not statistically different between the two groups 
(41.7% in the ezetimibe/simvastatin group vs. 44.7% in the at-
orvastatin group). Also, the percentage reduction of LDL-C 
from baseline was similar (ezetimibe/simvastatin group 41% 
vs. atorvastatin group 44%). Both fulfilled the recommenda-
tion that intensity of therapy be sufficient to achieve at least 
a 30% to 40% reduction in LDL-C levels.
13)
However, this study showed discrepancy in percentage re-
duction of LDL-C as compared with other studies although 
there was no similar study which compared the efficacy of 
lipid-lowering agents in very high-risk patients. The Vytorin 
Versus Atorvastatin (VYVA) study showed 50.6% reduction 
of LDL-C in ezetimibe/simvastatin 10/20 mg treatment and 
43.7% reduction in atorvastatin 20 mg treatment.
10) In the pre-
vious study which evaluated the efficacy of ezetimibe/simv-
astatin and atorvastatin in patients with type 2 diabetes mel-
litus and hypercholesterolemia, the percent change of LDL-C 
from baseline in ezetimibe/simvastatin 10/20 mg was 53.6% 
and atorvastatin 20 mg was 44.6%.
14) Although the inclusion 
criteria in each study were different, the reduction of LDL-C 
in atorvastatin 20 mg was similar. However, the percentage 
reduction of LDL-C in ezetimibe/simvastatin 10/20 mg was 
greater than that of the present study. The most important 
and likely explanation may be the small number of patients. 
A different baseline of the characteristics of enrolled patients 
may also be related. Majority of patients in the present study 
were ACS (66.7% in ezetimibe/simvastatin group vs. 65.8% in 
atorvastatin group). The efficacy of atorvastatin in ACS was 
already proved by PROVE-IT-TIMI 22 study.
12) However, the 
study regarding the efficacy of ezetimibe/simvastatin in ACS 
has still been investigated.
15) The other explanation may be 
drug compliance, which was evaluated only by interviews with 
the patients.
The tolerability elicited by both drugs in the present study 
was consistent with previous reports.
11)16-19) Overall incidence 
of adverse events was low in both groups.
This study evaluated the efficacy of ezetimibe/simvastatin 
10/20 mg and atorvastatin 20 mg in a small number of very 
high-risk patients. Although this study did not show any dif-
ference in reaching target LDL-C goal as well as in reducing 
LDL-C from baseline after 6-week follow-up, it was useful 
because it was performed on Korean patients with very-high 
risk. This data revealed that ezetimibe/simvastatin 10/20 mg 
or atorvastatin 20 mg was still under the correct dose to pa-
tients with very-high risk including ACS. Therefore, more 
potent lipid-lowering therapy will be considered to achieve 
their LDL-C level goal.
This study has several limitations. Although the number of 
patients was calculated by LDL-C lowering effect of two drugs, 
the major limitation was the small number of patients. In ad-
dition, according to the VYVA study,
10) the potency between 
ezetimibe/simvastatin 10/20 mg and atorvastatin 20 mg was 
not comparable in overall hypercholesterolemia although 
this result could not completely apply to Korean patients be-
cause of different disease characteristics and racial difference. 
Furthermore, almost all the enrolled patients were ACS and 
this could affect the change of lipid parameters. One impor-
tant aspect of this study was that ezetimibe/simvastatin 10/20 
mg and atorvastatin 20 mg did not attain the target LDL-C 
goal in more than half of the patients. A comparison of a hi-
gher dosage of ezetimibe/simvastatin and atorvastatin with 
a large population compared to the current study will be help-
ful to clarify the efficacy and tolerability in Korean patients 
with very high-risk.
In summary, ezetimibe/simvastatin 10/20 mg and atorvas-
tatin 20 mg showed similar effectiveness in achieving a tar-
get LDL-C goal and lipid-lowering effect in Korean patients 
with very high risk, especially in ACS. Furthermore, a higher 
dose compared to ezetimibe/simvastatin 10/20 mg and ator-
vastatin 20 mg will be needed to attain a better rate of target 
LDL-C goal in this patient subset.
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